(CercleFinance.com) – Inventiva announces the screening in the United States of the first patient in its Phase IIa clinical trial LEGEND combining lanifibranor and empagliflozin in patients with NASH (non-alcoholic steatohepatitis) and type 2 diabetes (T2D) .
The trial will be conducted double-blind for the ‘placebo’ and ‘lanifibranor’ arms and open-label for the arm combining lanifibranor and empagliflozin. A total of 63 patients with non-cirrhotic NASH and T2D are expected to be recruited into LEGEND.
More than 30 sites located in France, the United Kingdom, Belgium, the Netherlands and the United States have already been qualified to participate in this clinical trial. The publication of the first results is scheduled for the second half of 2023.